A randomized controlled study of the effects of remazolam tosylate on early cognitive function and related inflammatory factors after painless endoscopic diagnosis and treatment in elderly patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047784

Enrollment

Unknown

Registered

2021-06-26

Start date

2021-06-28

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless endoscopic diagnosis and treatment of elderly patients

Interventions

Experimental group:Initial dose of remazolam tosylate group: 0.3 mg/kg, additional maintenance dose: 2.5 mg

Control group1:Initial dose of propofol: 1.5 mg/kg, additional maintenance dose: 0.5 mg/kg

Control group2:Give the same volume of normal saline control

Eligibility

Sex/Gender

Male

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients undergoing selective digestive endoscopy diagnosis and treatment; 2.Age less than or equal to 60 years old, ASA i-ii level; 3.Sign informed consent and voluntarily participate in this experiment.

Exclusion criteria

Exclusion criteria: 1. Preoperative depression, cognitive impairment; 2. Hearing or visual impairment; 3. Taking drugs, alcohol or taking antidepressants for a long time; 4. Those who have had a cardio-cerebrovascular accident, neurological sequelae, or severe liver and kidney dysfunction within 6 months; 5. Those with BMI30; 6. Those who are confirmed or suspected of being allergic to the test drug.

Design outcomes

Primary

Measure	Time frame
tumor necrosis factor-a;interleukin-1;	—

Countries

China

Contacts

Public ContactChen Yongming

Hangzhou Bay Hospital of Ningbo City

13564932181@163.com+86 13564932181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026